Vir Biotechnology to Present at BofA Securities 2020 Health Care Conference
Vir Biotechnology (Nasdaq: VIR) has announced that its CEO, George Scangos, Ph.D., will present virtually at the BofA Securities 2020 Health Care Conference on May 14, 2020, at 12:40 pm PT / 3:40 pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vir Biotechnology (Nasdaq: VIR) has announced that its CEO, George Scangos, Ph.D., will present virtually at the BofA Securities 2020 Health Care Conference on May 14, 2020, at 12:40 pm PT / 3:40 pm ET. Investors and interested parties can access the live webcast through the Vir website, where it will also be archived for 30 days afterward. Vir Biotechnology focuses on treating serious infectious diseases using advanced immunologic technologies and has initiatives targeting various viruses, including SARS-CoV-2 and hepatitis B.
Details
News Market Reaction – VIR
The recorded move for VIR in the trading session of this news was +3.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., Chief Executive Officer will virtually present at the BofA Securities 2020 Health Care Conference on Thursday, May 14th at 12:40 pm PT/ 3:40 pm ET.
A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.
About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. For more information, please visit www.vir.bio.
Contact:
Vir Biotechnology, Inc.
Investors
Neera Ravindran, MD
Head of Investor Relations & Strategic Communications
nravindran@vir.bio
+1-415-506-5256
Media
Lindy Devereux
Scient PR
lindy@scientpr.com
+1-646-515-5730
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.